Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2015

View Archived Issues

Shionogi presents highlights of first quarter of fiscal 2015

Novel potent cross-reactive MAb that neutralizes influenza A virus

Novo Nordisk reviews second quarter 2015

New findings concerning the pathophysiology of spinal cord injury

Emergent BioSolutions plans to spin off immuno-oncology business

German and U.S. team presents omega-3 PUFA analogues

Allergan divulges prostanoid receptor antagonists

Piramal introduces EZH2 inhibitors

Daiichi Sankyo discloses LCAT activators

MabVax and Rockefeller University enter into research collaboration agreement

Inovio and MedImmune establish cancer vaccine collaboration

Anti-IL-23 therapy shows promise for the treatment of psoriasis

Sanofi, Evotec and Apeiron Biologics collaborate on development of immuno-oncology treatments

Phase I study investigates DNA vaccine pTVG-AR for metastatic prostate cancer

Merck & Co. divulges MGAT2 inhibitors

Cancer Research UK awards grant to Newcastle University's Northern Institute of Cancer Research

Sanofi files application for alirocumab approval in Japan

Torii and ALK's Japanese cedar pollen SLIT improves rhinitis symptoms in phase II/III trial

FDA grants orphan drug designation to recombinant IVIG-mimetic GL-2045

RegeneRx updates on clinical development of RGN-259

Antibe Therapeutics completes phase I development of ATB-346

SAGE Therapeutics and FDA agree design of phase III SAGE-547 trial under SPA

MJFF to fund preclinical study of ANAVEX 2-73 for Parkinson's disease

ProMetic Life Sciences completes first plasminogen dosing round in phase I trial

Turing acquires Daraprim U.S. rights from Impax

FDA approves Keveyis for primary hyperkalemic and hypokalemic periodic paralysis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...